Get the Stockscreener App
1.78
2.73%
-0.05
Pre-market:
1.67
-0.11
-6.18%
Stereotaxis Inc stock is traded at $1.78, with a volume of 359.03K.
It is down -2.73% in the last 24 hours and down -21.59% over the past month.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
See More
Previous Close:
$1.83
Open:
$1.82
24h Volume:
359.03K
Relative Volume:
0.87
Market Cap:
$178.78M
Revenue:
$25.14M
Net Income/Loss:
$-21.57M
P/E Ratio:
-6.5926
EPS:
-0.27
Net Cash Flow:
$-12.23M
1W Performance:
-1.66%
1M Performance:
-21.59%
6M Performance:
-17.97%
1Y Performance:
-28.51%
1-Day Range:
$1.725
$1.8278
1-Week Range:
$1.725
$1.895
52-Week Range:
$1.66
$3.29
Stereotaxis Inc Stock (STXS) Company Profile
Name
Stereotaxis Inc
Sector
Industry
Phone
314-678-6100
Address
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Compare STXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STXS
Stereotaxis Inc
|
1.78 | 178.78M | 25.14M | -21.57M | -12.23M | -0.27 |
|
ISRG
Intuitive Surgical Inc
|
476.78 | 170.05B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
222.79 | 63.97B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
86.81 | 42.94B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
219.72 | 32.28B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.55 | 17.64B | 17.28B | 108.00M | 391.00M | 0.20 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-24 | Initiated | ROTH MKM | Buy |
| Jul-12-22 | Initiated | Aegis Capital | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Jan-05-22 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | Loop Capital | Buy |
| May-26-21 | Initiated | Piper Sandler | Overweight |
| Sep-08-20 | Initiated | Northland Capital | Outperform |
| Apr-09-20 | Initiated | Cowen | Outperform |
| Apr-07-20 | Initiated | Lake Street | Buy |
View All
Stereotaxis Inc Stock (STXS) Latest News
Stereotaxis director Isaac Paul acquires $68,780 in common stock By Investing.com - Investing.com South Africa
Director Makes Bold Move with Major Stereotaxis Stock Purchase - TipRanks
Stereotaxis director Isaac Paul acquires $68,780 in common stock - Investing.com
Stereotaxis director Paul Isaac acquires $44,836 in common stock By Investing.com - Investing.com Canada
Stereotaxis director Paul Isaac acquires $44,836 in common stock - Investing.com Australia
Stereotaxis to Present at 37th Annual Roth Conference - GlobeNewswire
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission - Yahoo Finance
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn (NYSE:STXS) - Seeking Alpha
Q1 Earnings Estimate for Stereotaxis Issued By Roth Capital - Defense World
Stereotaxis, Inc. (AMEX:STXS) Q4 2024 Earnings Call Transcript - MSN
Stereotaxis submits catheter pair for FDA clearance - Robot Report
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval - MSN
Stereotaxis sees double digit revenue growth for FY25 - Yahoo Finance
Stereotaxis submits EMAGIN catheter for regulatory clearance - Yahoo Finance
Stereotaxis announces FDA regulatory submission for MAGiC Sweep catheter - Yahoo Finance
Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
Stereotaxis Earnings Call: Growth Amid Challenges - TipRanks
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Stereotaxis earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Stereotaxis Q4 2024 misses forecasts, stock dips By Investing.com - Investing.com Canada
Stereotaxis seeks FDA nod for robotic catheter system By Investing.com - Investing.com Canada
Stereotaxis seeks FDA nod for robotic catheter - Investing.com India
Stereotaxis seeks FDA nod for robotic catheter system - Investing.com India
Stereotaxis seeks FDA nod for robotic catheter By Investing.com - Investing.com South Africa
Stereotaxis Inc Reports Q4 2024 Earnings: EPS of -$0.09 Misses E - GuruFocus.com
Stereotaxis Reports 2024 Full Year Financial Results - The Manila Times
Stereotaxis Submits FDA Application for EMAGIN™ 5F, First Robotically Navigated Catheter for Endovascular Procedures - Nasdaq
Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance - GlobeNewswire
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery - GlobeNewswire
Can Stereotaxis Revolutionize Stroke and Cancer Treatment? New Robotic Catheter Heads to FDA - StockTitan
Could This First-Ever Robotic Mapping Catheter Transform Cardiac Procedures? - StockTitan
Can Stereotaxis Turn Q4 Momentum Into Sustained Growth After Flat 2024 Results? - StockTitan
Stereotaxis Reports Strong Revenue Growth and Strategic Milestones - TipRanks
Stereotaxis, Inc. to Host Earnings Call - ACCESS Newswire
Stereotaxis (STXS) to Release Quarterly Earnings on Monday - Defense World
Stereotaxis Inc (STXS) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Stereotaxis Inc (STXS) Q4 2024: Everything You Need To Know Ahea - GuruFocus.com
Stereotaxis (STXS) Projected to Post Quarterly Earnings on Monday - MarketBeat
Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference - GlobeNewswire
Global Magnetic Ablation Catheters Market Poised for Significant Growth, Projected to Reach USD 1,114.4 Million by 2035 Driven by Technological Advancements and Rising Cardiovascular Cases | Future Market Insights, Inc. - GlobeNewswire Inc.
Legato Capital Management LLC Sells 111,859 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) - MarketBeat
Stock Market Sleeps On Stereotaxis MAGiC CE Mark (NYSE:STXS) - Seeking Alpha
SG Americas Securities LLC Has $60,000 Holdings in Stereotaxis, Inc. (NYSEAMERICAN:STXS) - Defense World
STXS Stock Gains Following the First Order for its GenesisX - MSN
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - GlobeNewswire
Stereotaxis Inc Stock (STXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):